1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. TAM Receptor

TAM Receptor

Tyro3; Axl; Mer

TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells. The TAM family of receptors and their ligands Gas6 and Protein S (PROS1) are required for the optimal phagocytosis of apoptotic cells in the mature immune, nervous, and reproductive systems.

TAMs are three homologous type I receptor-tyrosine kinases that are activated by endogenous ligands, PROS1 and GAS6. These ligands can either activate TAMs as soluble factors, or, in turn, opsonize phosphatidylserine (PS) on apoptotic cells (ACs) and serve as bridging molecules between ACs and TAMs. Abnormal expression and activation of TAMs have been implicated in promoting proliferation and survival of cancer cells, as well as in suppressing anti-tumor immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9988
    Mecbotamab
    Inhibitor
    Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011).
    Mecbotamab
  • HY-150041
    TL4830031
    Inhibitor ≥98.0%
    TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent Axl inhibitor with an IC50 value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research.
    TL4830031
  • HY-147218
    PF-07265807
    Inhibitor
    PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer.
    PF-07265807
  • HY-132893
    AZ14145845
    Inhibitor
    AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
    AZ14145845
  • HY-12432S1
    Gilteritinib-d8
    Inhibitor ≥98.0%
    Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib-d<sub>8</sub>
  • HY-13016R
    Cabozantinib (Standard)
    Inhibitor
    Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2/KDR/Flk-1 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
    Cabozantinib (Standard)
  • HY-13016A
    Cabozantinib hydrochloride
    Inhibitor
    Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2/KDR/Flk-1 and MET, with IC50 values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
    Cabozantinib hydrochloride
  • HY-146615
    Axl-IN-6
    Inhibitor
    Axl-IN-6 (compound 14) is an orally active and potent AXL inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model.
    Axl-IN-6
  • HY-152830
    Adrixetinib
    Inhibitor 99.51%
    Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity.
    Adrixetinib
  • HY-153277
    Axl/Mer/CSF1R-IN-2
    Inhibitor
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.
    Axl/Mer/CSF1R-IN-2
  • HY-147576
    Axl-IN-9
    Inhibitor
    Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC50 of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals.
    Axl-IN-9
  • HY-147578
    Axl-IN-11
    Inhibitor
    Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals.
    Axl-IN-11
  • HY-144624
    PROTAC Axl Degrader 1
    Inhibitor
    PROTAC Axl Degrader 1 is a potent and selective PROTAC Axl degrader with an IC50 of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces mehuosis.
    PROTAC Axl Degrader 1
  • HY-146014
    Multi-kinase-IN-1
    Inhibitor
    Multi-kinase-IN-1 (Compound 11k) is a potent kinase inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell apoptosis, and can be studied for colorectal cancer.
    Multi-kinase-IN-1
  • HY-144708
    Axl-IN-4
    Inhibitor
    Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC50 of 28.8 μM.
    Axl-IN-4
  • HY-162085
    Axl-IN-17
    Inhibitor
    Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy.
    Axl-IN-17
  • HY-147577
    Axl-IN-10
    Inhibitor
    Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC50 of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals.
    Axl-IN-10
  • HY-120387
    SMU-B
    Inhibitor
    SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models.
    SMU-B
  • HY-15150G
    Bemcentinib (GMP)
    Inhibitor
    Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC50 of 14 nM.
    Bemcentinib (GMP)
  • HY-149491
    HIV-IN-7
    Inhibitor
    Axl-IN-16 (Compound 4) is a Axl inhibitor. Axl-IN-16 inhibits Axl expression and inhibits the activity of HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 can be isolated from“fruiting liquid (FL)” of Hypholoma lateritium and Hericium erinaceus.
    HIV-IN-7
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.